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Abstract
Swine are an important host of Japanese encephalitis virus (JEV). The two membrane glycoproteins of JEV, prM and
E, each contain a potential N-linked glycosylation site, at positions N15 and N154, respectively. We constructed
plasmids that contain the genes encoding wild-type prME (contain the signal of the prM, the prM, and the E
coding regions) and three mutant prME proteins, in which the putative N-linked glycosylation sites are mutated
individually or in combination, by site-directed mutagenesis. The recombinant plasmids were used as DNA vaccines
in mice. Our results indicate that immunizing mice with DNA vaccines that contain the N154A mutation results in
elevated levels of interleukin-4 secretion, induces the IgG1 antibody isotype, generates greater titers of anti-JEV
antibodies, and shows complete protection against JEV challenge. We conclude that mutation of the putative N-
glycosylation site N154 in the E protein of JEV significantly enhances the induced humoral immune response and
suggest that this mutant should be further investigated as a potential DNA vaccine against JEV.
1. Introduction
Japanese encephalitis virus (JEV) belongs to the genus
Flavivirus, and the genus Flavivirus include many clini-
cally important pathogens, such as dengue virus
(DENV), West Nile virus (WNV), yellow fever virus,
Murray Valley encephalitis virus, St.Louis encephalitis
virus, and tick-borne encephalitis virus (TBEV). Japanese
encephalitis virus (JEV) mostly causes infection of the
central nervous system in humans and equines and still-
births in swine [1,2]. The virus is zoonotic, cycling
between birds and mosquitoes, and is transmitted to
humans by infected mosquitoes. Since swine serve as a
reservoir and amplifier of the virus [3], the development
of a swine vaccine against JEV is a high priority, as it
could help prevent epidemics in humans.
JEV contains a single-stranded, plus-sense RNA gen-
ome of ~11 kb. It consists of a single open reading
frame that codes for a large polyprotein of 3432 amino
acids that is co- and post-translationally cleaved into
three structural proteins (capsid, C; premembrane, prM;
and envelope, E) and seven nonstructural proteins [4,5].
Envelope is the major structural protein, and makes up
the surface of the avivirus particle. E protein has numer-
ous neutralization epitopes, which mediate attachment
to host cells, and a putative receptor-binding domain
that induces the host immune response [6,7]. Though
prM is able to fold independently of the E protein, cor-
rect folding of the E protein requires co-synthesis with
prM [8]. PrM interacts with E to form prM-E heterodi-
mers, which are important for the formation of imma-
ture virions[9,10], and the signal of the prM determine
translocation and orientation of inserted protein, hence
the topology of prM and E [11]. Therefore, the signal of
the prM and the prM protein play an important role in
maintaining its native conformation of E protein.
N-linked glycans of viral proteins play important roles
in modulating the immune response. Glycans can be
important for maintaining the appropriate antigenic
conformations, shielding potential neutralization epi-
topes, and may potentially alter the proteolytic
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susceptibility of proteins [12,13]. In the JE viruses, the
prM protein contains one putative N-linked glycosyla-
tion site, at N15. E protein also has one putative N-
linked glycosylation site, at N154. Studies with JEV,
TBEV and WNV have found that deletion of the N-
linked glycosylation site in prM or E led to a decrease
in virus release [14-16]. However, the effects of these
putative N-linked glycosylation sites on the immune
response to JEV remained elusive.
Our primary aim in this work was to investigate the
role of the putative prME N-linked glycosylation sites
in inducing an immune response. It is known that
immunizing mice with plasmids encoding the prM and
E glycoproteins of JEV provide varying degrees of pro-
tection against the virus [17]. In this study, we con-
structed plasmids containing both the wild-type prME
and mutant prME genes, in which the N-linked glyco-
sylation sites are mutated individually or in combina-
tion. The immunogenicity of the three prME
glycosylation mutants was evaluated in mice. We
determined that mutating N154 of prME significantly
enhanced the immune response in mice and propose
that this mutant should be explored as a swine vaccine
against JEV.
2. Materials and methods
2.1 Cells and virus
The NJ2008 strain (GQ918133) of JEV was isolated from
brain tissues of aborted fetuses of sows, which were
obtained from a piggery in the Jiangsu province in 2008.
The NJ2008 strain of JEV was propagated in baby ham-
ster kidney (BHK-21) cells (ATCC CCL-10) for the
plaque reduction neutralization test (PRNT) and chal-
lenge test. The supernatants of the infected cells were
clarified and stored at -80°C for animal challenge. The
viral titers of the supernatants were approximately 7.3 ×
108 PFU as determined by the PRNT. Monkey kidney
cells (Vero) (ATCC) used for recombinant plasmid
transfection were grown and maintained in Dubach’s
modified Eagle’s medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum, 100 μg/ml of
streptomycin, and 100 μg/ml of penicillin.
2.2 Construction of site-directed prME mutants
A single cDNA fragment containing genomic nucleo-
tides (nt) 390 to 2478 was amplified by reverse tran-
scriptase-mediated PCR (RT-PCR). The JEV forward
and reverse primers were 5’-TACGAATTCATGGG-
CAGAAAGCAAAAC-3 ’ and 5 ’-CATCTCGAGAG-
CATGCACATTGGTCGCTAA-3’, respectively.
Restriction enzyme sites for EcoRI and XhoI were
engineered into the 5’ and 3 ’ ends of the cDNA,
respectively. An in-frame translation termination
codon was introduced upstream of the XhoI restriction
site at the 3’ terminus. Amplified cDNA was digested
with EcoRI and XhoI and inserted into the EcoRI-XhoI
site of the eukaryotic expression plasmid vector pVAXI
(Invitrogen) (Figure 1). The Quikchange kit (Stragene)
was used to mutate the putative glycosylation sites in
the pVAXI-prME plasmid. The single mutants were
referred to as pVAXI-prME-M1 (mutation at N15 site
of prM) and pVAXI-prME-M2 (mutation at N154 site
of E). The double mutant was referred to as pVAXI-
prME-M3 (Table 1).
Figure 1 Schematic representation of the recombinant JEV plasmid pVAXI -prME. The Y symbol denotes the positions of the predicted
glycans in the prM and E proteins. The amino acid sequences of the prM and E glycosylation sites are expanded at the bottom of the figure.
Zhang et al. Virology Journal 2011, 8:138
http://www.virologyj.com/content/8/1/138
Page 2 of 7
2.3 Transfection and Western blotting
BHK-21 cells were seeded at a concentration of 2.5 ×
104 cells/well into 6-well tissue culture plate until the
cells reached approximately 70-80% confluence. Trans-
fection was performed with LipofectAMINE 2000 reagent
(Invitrogen) as specified by the manufacturer. The trans-
fected cells were collected at 48 h post-transfection and
lysed in buffer L (50 mM Tris, 150 mM NaCl, 2 mM
EDTA, 1% Triton X-100, 0.5 mM phenylmethylsulfonyl
sulfate, pH 7.5). The lysates were centrifuged at 10,000 ×
g for 10 min to clear cellular debris and inactivated at 56°
C for 1 h, and aliquots of each proteins were digested
with 500 U of peptide N-glycosidase F (PNGase F, New
England Biolabs) for 1 h at 37°C or mock digested as a
negative control. Samples were then analyzed under
denaturing conditions by 12% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE), and Western blotting was
performed using JEV-positive serum (kept in our labora-
tory). Detection was performed using chemilumines.
2.4 Mouse immunization
Four-week old female BALB/c mice were purchased
from the Animal Center of Nanjing Army Hospital,
Nanjing, China. All mice were maintained in sterile
cages in specific-pathogen-free environments. Five
groups of mice (fourteen mice per group) were
inoculated with one of the following plasmids: pVAX-
prME-WT, pVAX-prME-M1, pVAXI-prME-M2, pVAX-
prME-M3, and pVAX (control group). The mice
received 50 μg of recombinant plasmids intramuscularly
(IM) into each thigh (total dose 100 μg). All groups
were inoculated three times at 2-week intervals. Serum
samples were collected from the central tail vein before
immunization on days 7, 21 and 35 after the prime
immunization, and sera were stored at -20°C.
One week after the second boost immunization, four
mice from each group were sacrificed and their spleens
removed aseptically for in vitro splenocyte culture. The
remaining mice were challenged by i.p. injection of a
lethal dose of the JEV NJ2008 strain (5 × 106 PFU). Sur-
vival of the mice was monitored daily up to 15 days
post-challenge. All animal experiments were conducted
according to the guidelines approved by the Animal
Ethical and Experimental Committee of the Nanjing
Agricultural University.
2.5 ELISA assays to profile antibodies and measure
cytokine production
Antibody levels were measured in sera were collected on
days 7, 21 and 35 after the prime immunization. Anti-
body subtypes were analyzed by ELISA [18] with some
modifications. The 96-well Maxi-sorpTM plates (Nunc)
were coated overnight with purified JEV particles
(10 ng/ml) in 0.1 M sodium carbonate (pH~9.5). The
presence of IgG, IgG1 and IgG2a was measured using
HRP-conjugated antibodies that recognized each of the
subtypes. Production of IL-4 and IFN-g was measured in
serum samples collected from all five experiment groups
35 days after the prime immunization, using the com-
mercially available mice cytokine ELISA kits (RD, USA).
2.6 Plaque reduction neutralization assay (PRNT)
Neutralization antibodies elicited in immunized mice
were evaluated by PRNT as described previously [19].
Two fold serial dilutions of murine sera starting at 1:5
were tested. The percentage neutralization was calcu-
lated from the number of plaques obtained in the pre-
sence or absence of serum. The reciprocal of the highest
serum dilution giving at least 50% neutralization was
taken as the JEV neutralization titer.
2.7 Statistical analysis
All data analyses were conducted using SPSS biostatis-
tics software (version 16.0, SPSS Inc., Chicago, IL, USA).
3. Results
3.1 Expressions of JEV prME-WT and three mutant
proteins by Western blot analysis
Vero cells were transfected with pVAXI-prME-WT and
the three plasmids encoding the mutant prME genes,
pVAXI -prME-M1, pVAXI -prME-M2, and pVAXI
-prME-M3. To determine whether the mobility shift
observed for the JEV prME mutant proteins actually
reflected the loss of glycans at the potential N-linked gly-
cosylation sites, we treated or mock-treated immunopre-
cipitated lysates with PNGase F, which cleaves all types
of N-linked glycans. The digestion of approximate 77
kDa prME-WT protein with PNGase F yielded a product
of approximate 70 kDa, and the digestion of approximate
74 kDa prME- M1 protein with PNGase F yielded a pro-
duct of approximate 70 kDa, whose migration pattern
was invariably identical to those of prME-M2 protein.
However, both the mock- and PNGase F-digested prME-
M3 protein migrated at the same position as the PNGase
F-digested prME-WT protein (Figure 2A). b-actin, a
Table 1 pVAX-prME mutant vectors and predicted
glycosylation patterns
Name Mutation site Glycosylation
prM-15 E-154 prM E
pVAX-prME-wt Asn Asn Thr Asn Tyr Ser + +
pVAX-prME-M1 Ala Ɵ Asn Thr Asn Tyr Ser - +
pVAX-prME-M2 Asn Asn Thr Ala Ɵ Tyr Ser + -
pVAX-prME-M3 Ala Ɵ Asn Thr Ala Ɵ Tyr Ser - -
Amino acid residues of JEV prME protein targeted for mutagenesis. prME -M1
and prME -M2 are single site mutants, whereas prME -M3 is the double
mutant. In all mutants, the Asn codon was replaced by an Ala codon in its N-
glycosylation sites (N-X-T/S). Asterisks represent mutated N-glycosylation sites.
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housekeeping gene with constant expression, was used as
internal control (Figure 2B).
3.2 Antibody isotype profiles
The induction of prME-specific IgG antibodies in each of
the animal groups was monitored by ELISA after immu-
nization. JEV-prME specific antibody responses were
induced following the first vaccination and increased fol-
lowing each booster. With respect to IgG and IgG1, vac-
cination with the prME-M2 and prME-M3 plasmids
produced a stronger response than WT (Figure 3A,B).
However, no significant differences were observed among
the IgG2a antibody titers upon vaccination with any of
the plasmids (Figure 3C). The strong IgG1 response pre-
sent in animals immunized with prME-M2 and prME-
M3 suggests a strong Th2-type immune response.
3.3 Cytokine response to prME mutants
Cellular immunity was evaluated by measuring the pro-
duction of IFN-g and IL-4 in spleen lymphocytes har-
vested 72 h after the second booster. As shown in
(Figure 4), spleen lymphocytes from mice immunized
with prME-M2 and prME-M3 secreted large amounts of
IL-4, though the level of IFN-g in these animals was not
as elevated. Splenocytes from mice immunized with
prME-WT and prME-M1, however, produced low levels
of IL-4 and high levels of IFN-g. Our results suggest
that splenocytes from mice immunized with prME-M2
and prME-M3 predominantly induced a Th2-type
immune response, because the levels of Th2-type cyto-
kines (IL-4) were higher than those of Th1-type cyto-
kines (IFN-g). Thus, it appears that mutation of N154 in
prME induces strong production of Th2 cytokines.
3.4 Production of neutralizing antibodies
Serum samples collected 35 days after the prime immu-
nization were evaluated for the ability to neutralize JEV
in plaque reduction neutralization assays. As shown in
Table 2, the neutralization titer of serum from the
prME-WT-immunized mice was very low, consistent
with previous report. According to the previous report,
in the process of JEV DNA vaccine, the low lever of
neutralization titer could significantly produce the high
protection rate after challenge [19]. However, the neu-
tralization titers of serum from prME-M2- and prME-
M3-immunized mice were higher than those induced by
mice immunized with prME-WT and prME-M1. Neu-
tralizing antibodies were not detected in controls. Our
results suggest that mutating N154 in prME induces
strong neutralizing antibody response.
3.5 Protection against JEV challenge in immunized mice
To investigate the degree to which the immunized mice
were protected from JEV, all immunized mice were
exposed to a lethal dose of the JEV strain NJ2008 and
evaluated for their ability to survive the challenge. Mice
immunized with prME-M2 or prME-M3 showed com-
plete protection against JEV challenge. Nine out of ten
mice immunized with prME-WT and prME-M1 sur-
vived JEV challenge, whereas only one mouse in the
control group survived (Table 2).
Discussion
Japanese encephalitis (JE) is a serious disease prevalent
throughout Asia [20] and is transmitted to humans by
mosquito bite [21]. Pigs are an important amplifier host
for the virus [22] Vaccination of swine, therefore, can
help prevent disease in humans [23].
DNA vaccines against JEV have shown great potential
as preventative agents for their ability to elicit potent
humoral and cytotoxic cellular immune responses
against the plasmid-encoded protein in a broad range of
hosts [24]. A previous study demonstrated that plasmids
carrying the JEV prM and E genes can induce high
NEUT antibodies and protective immunity in mice.
Most importantly, the signal of prM is included in DNA
vaccine, thus it is likely that viral antigens can be
secreted from transfected cells and these DNA vaccines
can induce high levels of immune responses [11]. In this
study, we assessed the immunogenicity of several prME
mutants to evaluate the potential of these mutants as
DNA vaccines against JEV in swine.
Figure 2 Western blotting analysis of the expression of recombinant plasmids and b-actin. (A)Samples were harvested from cell lysates at
48 h after transfection. prME-WT, prME-M1, PVAX-prME-M2, and PVAX-prME-M3 proteins were incubated with PNGase F (+) or buffer only (−). (B)
b-actin was used as internal control.
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The prM and E proteins of JEV are both exposed
structural proteins. E is a major immunogenic antigen,
and the prM is JEV induce protective immune addi-
tional components [25]. It has been reported that the
prM proteins of flaviviruses can form natively folded
structures independent of the E protein, form hetero-
dimers with the E protein, and appear to act as folding
chaperones for E protein [8]. In addition, the prME
expression plasmids contain the signal of prM coding
sequences for translocation into endoplasmic reticulum
(ER), and the signal of prM can make the respective
proteins are glycosylated or transported by the
Figure 3 Analysis of JEV-induced IgG isotypes. Prime-boost-boost vaccinations were carried out. On day 7 (prime), day 21 (first boost) and
day 35 (second boost) sera were taken and immunoglobulin isotypes were analyzed by ELISA. (A) IgG isotype response; (B) IgG1 isotype
response; (C) IgG2a isotype response. Data presented as mean ± standard error for fourteen mice per group. ƟP < 0.05 compared with groups
immunized with prME-WT in prime-boost-boost vaccinations.
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secretory pathway as supposed [11]. To investigate the
effect of mutating putative N-glycosylation sites on the
immunogenicity of prM and E, these proteins must
maintain their native conformation.
Previous studies have demonstrated that N-linked gly-
cans on the glycoproteins of many viruses play impor-
tant roles in modulating the immune response. Removal
of N-glycosylation sites in the simian immunodeficiency
virus envelope protein and influenza virus hemaggluti-
nin protein have been observed to limit the neutralizing
antibody response [26], while mutation of N-linked gly-
cans in human immunodeficiency virus type 1 (HIV-1)
envelope protein appears to enhance the production of
CTL [27], and deletion of glycans in hepatitis C virus E1
can enhance cellular or humoral immune responses
[28]. The effects of the putative N-linked glycosylation
sites in prM and E on the immune response to JEV are
not known, however.
The JEV PrM protein contains one putative N-linked
glycosylation site at N15, and the E protein also contains
one putative N-linked glycosylation site, at N154. We
demonstrate that immunization with the mutants prME-
M2 and prME-M3, both of which contain the N154A
mutation, induced a significantly enhanced antibody
response, elevated IL-4 secretion levels, and full protec-
tion to lethal challenge of JEV compared to immuniza-
tion with native prME, indicating that these mutations
could elicit a stronger humoral immune response than
the wild-type prME. We also demonstrate that mutating
the N15 site (prME-M1) induces a humoral immune
response comparable to that observed upon immuniza-
tion with wild-type prME. This strongly suggests that
mutating N15 in the prM glycoprotein does not strongly
perturb the immune response to prME, but mutating
N154 of the E glycoprotein does affect the immune
response to prME.
Though DNA vaccines generally induce a stronger
Th1 immune response, producing elevated levels of
IFN-g and IgG2a, the immune responses induced by
DNA vaccines need to be improved. Our results show
that a single mutation, N154A, significantly enhances
the humoral immune response. We propose, therefore,
that this highly immunogenic mutant could serve as a
swine vaccine against JEV and should be further opti-
mized for this purpose.
Figure 4 Cytokine detection in splenocyte culture supernatants from vaccinated mice. Splenocyte samples (n = 4 mice per group)
isolated from the spleens of vaccinated mice on day 35 after the prime immunization were stimulated with purified JEV particles (10 ng/ml).
After 72h, the supernatants were collected to examine the levels of the Th1-type cytokine IFN-g and the Th2-type cytokine IL-4 using
commercially available murine cytokine ELISA kits. Data presented as mean ± standard error for four mice per group.
Table 2 The neutralization titers of serum and protective
immunity in vaccinated mice
DNA Vaccine PRNT50 Survival rate (%)
pVAXⅠprME-WT 13 ± 4 90b
pVAXⅠprME-M1 15 ± 5 90b
pVAXⅠprME-M2 35 ± 9a 100b
pVAXⅠprME-M3 38 ± 8a 100b
pVAXⅠ(Control) < 5 10
Data are shown as mean ± standard error (S.E.). Statistical analysis was
performed using Student’s t-test.
aSignificance (P < 0.05 to 13 ± 4 and 15 ± 5).
bSignificance (P < 0.05 to 10%).
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